Top

Published in:

01-02-2018 | Original Paper

Neuropathology of iatrogenic Creutzfeldt–Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology

Authors: Charles Duyckaerts, Véronique Sazdovitch, Kunie Ando, Danielle Seilhean, Nicolas Privat, Zehra Yilmaz, Laurène Peckeu, Elodie Amar, Emmanuel Comoy, Aleksandra Maceski, Sylvain Lehmann, Jean-Pierre Brion, Jean-Philippe Brandel, Stéphane Haïk

Published in: Acta Neuropathologica | Issue 2/2018

Abstract

Abeta deposits and tau pathology were investigated in 24 French patients that died from iatrogenic Creutzfeldt–Jakob disease after exposure to cadaver-derived human growth hormone (c-hGH) in the 1980s. Abeta deposits were found only in one case that had experienced one of the longest incubation periods. Three cases had also intracellular tau accumulation. The analysis of 24 batches of c-hGH, produced between 1974 and 1988, demonstrated for the first time the presence of Abeta and tau contaminants in c-hGH (in 17 and 6 batches, respectively). The incubation of prion disease was shorter in the French patients than the incubation times reported in two previously published British series. We interpreted the low incidence of Abeta in this French series as a consequence of the shorter incubation period observed in France, as compared to that observed in the United Kingdom. This concept suggested that a mean incubation period for the development of detectable Abeta deposits would be longer than 18 years after the first exposure. Moreover, we hypothesized that tau pathology might also be transmissible in humans.

Available only for authorised users

Abbott A (2016) The red-hot debate about transmissible Alzheimer’s. Nature 531:294–297. https://doi.org/10.1038/531294a CrossRefPubMed

Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178:803–816. https://doi.org/10.1016/j.ajpath.2010.10.034 CrossRefPubMedPubMedCentral

Audouard E, Houben S, Masaracchia C, Yilmaz Z, Suain V, Authelet M, Dedecker R, Buée L, Boom A, Leroy K, Ando K, Brion J (2016) High molecular weight PHF from Alzheimer brain induce seeding of wild-type mouse tau into an argyrophilic 4R tau pathology in vivo. Am J Pathol 186:2709–2722CrossRefPubMed

Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357CrossRefPubMed

Brown P, Brandel JP, Preece M, Sato T (2006) Iatrogenic Creutzfeldt–Jakob disease: the waning of an era. Neurology 67:389–393CrossRefPubMed

Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d’Aignaux JH, Cervenakova L, Fradkin J, Schonberger LB, Collins SJ (2000) Iatrogenic Creutzfeldt–Jakob disease at the millennium. Neurology 55:1075–1081CrossRefPubMed

Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913CrossRefPubMedPubMedCentral

Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M, Tolnay M (2014) Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol 127:299–301. https://doi.org/10.1007/s00401-013-1231-5 CrossRefPubMed

de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A (2003) Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29:288–302CrossRefPubMed

10.

Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980–982. https://doi.org/10.1126/science.1194516 CrossRefPubMedPubMedCentral

11.

Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D, Kaminski CF, Winkler DT, Maetzler W, Keyvani K, Spitzer P, Wiltfang J, Kaminski Schierle GS, Zetterberg H, Staufenbiel M, Jucker M (2014) Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal fluid. Brain 137:2909–2915. https://doi.org/10.1093/brain/awu255 CrossRefPubMedPubMedCentral

12.

Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc’h K, Schraen S, Buee L, Pasquier F, Hugon J, Touchon J, Lehmann S (2013) Impact of the 2008–2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis 34:297–305. https://doi.org/10.3233/JAD-121549 PubMed

13.

Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ, Haik S, Fociani P, Bugiani O, Tagliavini F (2008) Tauopathy in human and experimental variant Creutzfeldt–Jakob disease. Neurobiol Aging 29:1864–1873. https://doi.org/10.1016/j.neurobiolaging.2007.04.026 CrossRefPubMed

14.

Hashizume M, Takagi J, Kanehira T, Otake K, Mimuro M, Yoshida M, Hashizume Y (2011) Histologic study of age-related change in the posterior pituitary gland focusing on abnormal deposition of tau protein. Pathol Int 61:13–18. https://doi.org/10.1111/j.1440-1827.2010.02610.x CrossRefPubMed

15.

Hunter S, Brayne C (2017) Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research? J Negat Results Biomed 16:1. https://doi.org/10.1186/s12952-017-0066-3 CrossRefPubMedPubMedCentral

16.

Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VM, Trojanowski JQ (2013) Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 70:462–468. https://doi.org/10.1001/jamaneurol.2013.1933 CrossRefPubMedPubMedCentral

17.

Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, Rudge P, Collinge J, Brandner S (2015) Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 525:247–250CrossRefPubMed

18.

Levavasseur E, Laffont-Proust I, Morain E, Faucheux BA, Privat N, Peoc’h K, Sazdovitch V, Brandel JP, Hauw JJ, Haik S (2008) Regulating factors of PrP glycosylation in Creutzfeldt–Jakob disease—implications for the dissemination and the diagnosis of human prion strains. PLoS ONE 3:e2786CrossRefPubMedPubMedCentral

19.

Malia TJ, Teplyakov A, Ernst R, Wu SJ, Lacy ER, Liu X, Vandermeeren M, Mercken M, Luo J, Sweet RW, Gilliland GL (2016) Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. Proteins 84:427–434. https://doi.org/10.1002/prot.24988 CrossRefPubMedPubMedCentral

20.

Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784CrossRefPubMed

21.

Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39:669–673. https://doi.org/10.1002/jnr.490390607 CrossRefPubMed

22.

Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P, Gelpi E, Giaccone G, Hauw JJ, Hoftberger R, Ironside JW, Jansen C, Kovacs GG, Rozemuller A, Seilhean D, Tagliavini F, Giese A, Kretzschmar HA (2012) Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124:517–529. https://doi.org/10.1007/s00401-012-1002-8 CrossRefPubMedPubMedCentral

23.

Peoc’h K, Levavasseur E, Delmont E, De Simone A, Laffont-Proust I, Privat N, Chebaro Y, Chapuis C, Bedoucha P, Brandel JP, Laquerriere A, Kemeny JL, Hauw JJ, Borg M, Rezaei H, Derreumaux P, Laplanche JL, Haik S (2012) Substitutions at residue 211 in the prion protein drive a switch between CJD and GSS syndrome, a new mechanism governing inherited neurodegenerative disorders. Hum Mol Genet 21:5417–5428CrossRefPubMed

24.

Pletnikova O, Rudow GL, Hyde TM, Kleinman JE, Ali SZ, Bharadwaj R, Gangadeen S, Crain BJ, Fowler DR, Rubio AI, Troncoso JC (2015) Alzheimer lesions in the autopsied brains of people 30 to 50 years of age. Cogn Behav Neurol 28:144–152. https://doi.org/10.1097/WNN.0000000000000071 CrossRefPubMedPubMedCentral

25.

Privat N, Laffont-Proust I, Faucheux BA, Sazdovitch V, Frobert Y, Laplanche JL, Grassi J, Hauw JJ, Haik S (2008) Human prion diseases: from antibody screening to a standardized fast immunodiagnosis using automation. Mod Pathol 21:140–149CrossRefPubMed

26.

Reiniger L, Lukic A, Linehan J, Rudge P, Collinge J, Mead S, Brandner S (2011) Tau, prions and Abeta: the triad of neurodegeneration. Acta Neuropathol 121:5–20. https://doi.org/10.1007/s00401-010-0691-0 CrossRefPubMed

27.

Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28:595–599. https://doi.org/10.1038/nbt.1641 CrossRefPubMedPubMedCentral

28.

Ritchie DL, Adlard P, Peden AH, Lowrie S, Le Grice M, Burns K, Jackson RJ, Yull H, Keogh MJ, Wei W, Chinnery PF, Head MW, Ironside JW (2017) Amyloid-beta accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol 134:221–240. https://doi.org/10.1007/s00401-017-1703-0 CrossRefPubMedPubMedCentral

29.

Riudavets Mena H, Bouffard JP, Sandberg G, Rushing EJ (2005) Relationship between radiation injury and Alzheimer-related neurodegenerative changes. Clin Neuropathol 24:236–238PubMed

30.

Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JD, Brandner S, Hyare H, Mead S, Collinge J (2015) Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain 138:3386–3399. https://doi.org/10.1093/brain/awv235 CrossRefPubMedPubMedCentral

31.

Schultz C, Ghebremedhin E, Braak H, Braak E (1997) Neurofibrillary pathology in the human paraventricular and supraoptic nuclei. Acta Neuropathol 94:99–102CrossRefPubMed

Title: Neuropathology of iatrogenic Creutzfeldt–Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology
Authors: Charles Duyckaerts
Véronique Sazdovitch
Kunie Ando
Danielle Seilhean
Nicolas Privat
Zehra Yilmaz
Laurène Peckeu
Elodie Amar
Emmanuel Comoy
Aleksandra Maceski
Sylvain Lehmann
Jean-Pierre Brion
Jean-Philippe Brandel
Stéphane Haïk
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 2/2018
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-017-1791-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neuropathology of iatrogenic Creutzfeldt–Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis

Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis

The function of the cellular prion protein in health and disease

Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas

Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis

Cofactors influence the biological properties of infectious recombinant prions